Colitis, UlcerativeINTENTNCT03532932
A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
An observational study of Colitis, Ulcerative and Crohn Disease, run by Takeda at 36 sites in 3 countries.
Trial summary
The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- How many people
- 1,990 participants
- Where
- 36 sitesin 3 countries
- Study dates
- 20 Jul 2018to 8 Nov 2021
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants diagnosed with moderate to severe UC or CD will be observed both retrospectively and prospectively.
Who may be able to join
- Has confirmed diagnosis of CD or UC for at least 2 years prior to enrollment in the study.
- Has a moderate to severe IBD flare at the time of enrollment or in participant anamnesis within 2 years before enrollment treated with steroids or/ and immunosuppressive agents or/ and biologic therapy. IBD flare(s) must be confirmed in the source documentation.
- Current treatment with steroids or/ and immunosuppressive agents or/ and 5-aminosalicylate (ASA) or/ and biologic therapy.
Who cannot join
- Current or previous (within the last two years) indeterminate or not classified colitis.
- Changing of IBD type in anamnesis (that is, from UC to CD, etc) within the last two years.
- Current, previous (within the last two years) or planned (for the next one year) participation in interventional clinical trial.
- Presenting of mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- Has received previous treatment with biologic therapy/immunosuppressive agents for conditions other than IBD ever in their lifetime.
Trial locations and contacts
36 sites in 3 countries.
36 sites in 3 countries
Russia31 sites
Regional Clinical Hospital
Barnaul, Altai Territory, 656024
State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical hospital"
Chelyabinsk, Chelyabinsk Oblast, 454076
Federal State Budgetary Educational Institution of Higher Education "Chita state medical academy" of the Ministry of Health of the Russian Federation
Chita, Zabaykalskiy (Transbaikal) Kray, 672000
State Budgetary Healthcare Institution Irkutsk Order of the Badge of Honor Regional Clinical Hospital
Irkutsk, Irkutsk Oblast, 664049
Budgetary Institution of Health in the Republic of Udmurtia First Republican Clinical Hospital under the Ministry of Health, the Republic of Udmurtia
Izhevsk, Udmurtiya Republic, 426039
Republican Clinical Hospital Ministry of health Republic of Tatarstan
Kazan', Tatarstan Republic, 20064
State Autonomous Healthcare Institution of Kemerovo region "Kemerovo regional clinical hospital n. a. S.V. Belyaev"
Kemerovo, Kemerovo Oblast, 650066
Regional State Budgetary Healthcare Institution "Regional Clinical Hospital # 1 n. a. S.I. Sergeev"
Khabarovsk, Khabarovsk Territory, 680009
State Budgetary Institution "Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky".
Krasnodar, Krasnodarskiy Kray, 350086
MEDSI Clinical Hospital
Krasnogorsk, Moscow Oblast, 150062
Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after IS Berzon
Krasnoyarsk, Krasnoyarsk Region, 660123
Moscow Clinical Scientific Center
Moscow, Moscow Oblast, 111123
State Scientific Center of Coloproctology
Moscow, Moscow Oblast, 123423
State Budgetary Healthcare Institution Moscow Regional Research and Clinical Institute (MONIKI) n. a. M. F. Vladimirskiy
Moscow, Moscow Oblast, 129110
Regional Clinical Hospital
Omsk, Omsk Oblast, 644111
Perm regional clinical hospital
Perm, Perm Krai, 614990
Federal State Budget Educational Institution of Higher Education "Petrozavodsk State University"
Petrozavodsk, Republic of Karelia, 185910
State Budgetary Institution of Ryazan Region "City Clinical Hospital #4"
Ryazan, Ryazan Oblast, 390023
Federal State Budget Military Educational Institution of Higher Education "Military Medical Academy named after S.Kirov" of the Ministry of Defense of the Russian Federation
Saint-Petersburg, Leningradskaya Oblast', 194044
Scientific and Research Center "Eco-safety", LLC
Saint-Petersburg, Leningradskaya Oblast', 196143
St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
Saint-Petersburg, Leningradskaya Oblast', 197110
Medical Academy n. a. S. I. Georgievksiy Federal State Autonomous Educational Institution of Higher Education "Crimean State University n. a. V.I. Vernadskiy
Simferopol, Republic Crimea, 295007
State Budgetary Healthcare Institution Republic of Crimea "Republican clinical hospital n.a. N.A.Semashko"
Simferopol, Republic Crimea, 295017
Budgetary Institution "Surgut District Clinical Hospital"
Surgut, Khanty-Mansi Autonomous Okrug-Yugra, 628408
Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation
Ufa, Bashkortostan Republic, 450008
State Budgetary Healthcare Institution RB Regional Clinical Hospital G.G Kuvatov
Ufa, Ufa Region, 450005
State Budgetary Healthcare Institution City Clinical Hospital 21
Ufa, Ufa Region, 450071
State Healthcare Institution Ulyanovsk Regional Clinical Hospital
Ulyanovsk, Ulyanovsk Oblast, 432017
Regional Clinical Hospital
Vladimir, Vladimirskaya Oblast’, 600023
Society with limited liability "Medical Association" New Hospital "
Yekaterinburg, Sverdlovsk Oblast, 620109
Health Care Unit # 1 of Yoshkar-Ola city
Yoshkar-Ola, Republic of Maruy El, 424037
Kazakhstan3 sites
Scientific-Research Institute of Cardiology and Internal Diseases, Gastroentorology department
Almaty, Almaty Region, 050000
The Centre of Coloproctology based at City Hospital 1
Astana, Astana, 010000
Regional clinical hospital
Shymkent, Shymkent, 160000
Belarus2 sites
Republican Gastroenterology Center, City Clinical Hospital # 10
Minsk, Minsk Oblast, 220077
Vitebsk regional clinical specialized center
Vitebsk, Vitebsk Oblast, 210601
About this study
Official title: International, Multicentre, Non-Interventional Study To Evaluate Disease Control And Treatment Pattern In Patients With Moderate To Severe Inflammatory Bowel Disease In Real Life Practice
The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD).
Read the detailed description
This is a non-interventional, retrospective and prospective study of participants with IBD. This study will collect data to provide accurate and comprehensive information related to treatment patterns associated with biologics use or non-biological therapy in participants with moderate to severe UC and CD in routine clinical practice.
The study will have retrospective data collection from past records of participants within the last 2 years before participant's enrollment. The prospective part of the study will include one year of observation and data collection after the participant's enrollment in the study.
The study will enroll approximately 2000 participants. Participants will be enrolled in one of the two groups:
- UC Participants
- CD Participants
This multi-center trial will be conducted in Russia, Belarus and Kazakhstan. The overall period of observation in this study will be approximately 12 months. Participants will make 2 visits within their routine practice to the clinic after the enrollment into the study including a final visit at Month 12.
- Keywords
- Drug therapy
- Medical subject headings
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| UC Participants | Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies. | |
| CD Participants | Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD
Treatment pattern with biologics agents or non-biological therapy included unique treatments combinations, Like>5-ASA1(Start with 5-ASA:5-ASA→Systemic biologics [SB] +/- STER+/-standard therapy[ST]),>5ASA2(without [w/o] STER),>5ASA3(5-ASA→STER+/-ST),>5ASA4(5-ASA→IS),>5ASA 5(5-ASA→5-ASA+/-IS),>5ASA6(5-ASA→ NOTR),>5ASA7(5-ASA),>NOTR1(NOTR→Biologics [BIO]+/-ST+/-STER),>NOTR 2(TR→ST+/-STER),>NOTR 3(NOTR),>IS1(IS→SB+STER+/-ST),>IS2(IS→SB+ST w/o STER),>IS 3(IS→STER+/-ST),>IS4(IS→5-ASA),>IS5(IS→NOTR),>IS6(IS→5-ASA+IS),>IS7(IS mono),>IS+5ASA1(IS+5-ASA→SB +/-ST),>IS+5ASA2(IS+5-ASA→SB ±ST w/o STER),>IS+5ASA3(IS+5-ASA→STER+/-ST),>IS+5ASA4(IS+5-ASA→NOTR),>IS+5ASA5(IS+5-ASA→IS),>IS+5ASA6(IS+5-ASA→5-ASA),>IS+5ASA7(IS+5-ASA),>BIO1(SB+/-STER+/-ST→withdrawal [w/d] of SB+ST+/-STER),>BIO2(SB+/-STER+/-ST),>BIO3(SB+/-STER+/-ST→NOTR),>BIO4(SB+/-STER+/-ST→SB mono),>STER1(STER+/-ST→w/d of STER+SB+/-ST),>STER2(STER+/-ST→w/d of STER+ST),>STER3(STER+/-ST→SB+STER+/-ST),>STER4(STER+/-ST→NOTR),>STER5(STER+/-ST).
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Secondary outcomes (12)
Number of Participants Stratified by Location of Disease
Measured: Within 1 year prior to Baseline (Visit 1)
Number of Participants Stratified by Disease Severity
Disease Severity was defined using Harvey-Bradshaw Index (HBI) and mayo index. HBI is validated clinical index for evaluation of CD disease severity, including the 5 categories: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25, where score less than (<) 5 was remission, score 5-7 was mild activity, score 8-16 was moderate, and score >16 was severe. Mayo index was used for evaluation of UC disease severity. Mayo index is an instrument consisting of 4 categories of: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment, each sub score graded from 0 to 3. The score ranges from 0 to 12, where score <2 was remission, score 3-5 was mild, score 6-10 was moderate, and score >10 was severe.
Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
Number of Participants Based on Usage of Methods for Documentation of Disease Activity in Routine Practice
Disease activity assessment was performed using following methods- biomarkers, endoscopy, biopsy, X-ray, magnetic resonance imaging (MRI) and ultrasound examination. Number of participants whose disease activity was evaluated using the respective methods were reported.
Measured: From Baseline Visit (Day 1) up to 12 months
Number of Assessments Using Different Methods in Participants With UC and CD Disease Activity
Disease activity assessment was performed using following methods- biomarkers, endoscopy, biopsy, X-ray, MRI and ultrasound examination. Biomarkers was based on evaluation of C-reactive protein (CRP) and/or fecal calprotectin levels. Endoscopy included colonoscopy/rectoromanoscopy/sigmoidoscopy and/or video capsule endoscopy and/or esophagogastroduodenoscopy (in the presence or suspicion of the presence of lesions of the upper gastrointestinal tract in Crohn's disease), X-ray was used for examination of the intestine to exclude stricturing and other lesions, MRI was used for examination of the intestine to exclude stricturing and other lesions using MRI and ultrasound for examination of the intestine to exclude stricturing and other lesions. Number of assessments using different methods in participants with UC and CD disease activity was summarized for specified methods and reported in terms of mean and standard deviation.
Measured: From Baseline Visit (Day 1) up to 12 months
UC Participants: Percentage of Participants Who Achieved Combined Clinical and Endoscopic Remission Based on Mayo Index
The full Mayo index is an instrument to measure disease activity of UC. It consists of 4 parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score ranged from 0 (normal or inactive disease) to 3 (severe activity). The score ranged from 0 to 12, where score <2 was remission, score 3-5 was mild activity, score 6-10 was moderate activity, and score >10 was severe activity. Higher scores indicating higher disease activity.
Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
CD Participants: Percentage of Participants Who Achieved Clinical Remission Based on HBI
HBI was used for evaluation of CD remission. It is a validated clinical index for CD, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25, where score <5 was remission, score 5-7 was mild activity, score 8-16 was moderate activity, and score >16 was severe activity. Higher scores indicating higher disease activity.
Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
Number of Participants With at Least One Episode of Failure of Biological or Non-biological Therapy
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Number of Participants Who Needed Treatment Adjustments Based on Disease Activity Assessment
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Stratified by Achieving the Treatment Goals
Treat to target (T2T) approach was used for assessment of treatment goals. A "Treat to target" approach for UC included clinical remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as Mayo endoscopic subscore of 0-1). Biomarker remission (normal C-reactive protein [CRP] and calprotectin) was considered as an adjunctive target. Histological remission was considered as an adjunctive goal. Clinical remission for CD was defined as resolution of abdominal pain and diarrhea/altered bowel habit. Endoscopic remission for CD was defined as resolution of ulceration at ileocolonoscopy or resolution of findings of inflammation on cross-sectional imaging in participants who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal CRP and faecal calprotectin) was considered as an adjunctive target.
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Challenges of Implementing a T2T Strategy in UC and CD Participants in Real Clinical Practice
"Other" challenges included absence or inaccessibility of MRI (technical problems), participants financial difficulties, disability and bureaucratic problems, unavailability of biotherapy, limited quotas, referral of participants to other centers, absence of biotherapy treatment quotas, difficulty in performing computed tomography (CT).
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Hospitalizations Due to Complications, IBD Related Surgeries, and Disability Determination in Participants With Moderate to Severe UC and CD
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Surgical Treatment by Indications and Type of Surgeries
Indications for surgical treatment included aggravation, intestinal bleeding, colon perforation, internal fistulas, abdominal cavity infiltrate, Interintestinal or Intraabdominal abscess, strictures in the gastrointestinal tract, anal fissures, and other. Types of surgeries includes both emergency and planned.
Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2018
- Study start20 Jul 2018
- Primary completion8 Nov 2021
- Study completion8 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Colitis, UlcerativeStudies of the same condition, open and under way.
- More trials run by TakedaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 1,990 participants (actual)
Sponsor and investigators
- Lead sponsor
- Takeda
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Study Director, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03532932
- Sponsor's protocol ID
- IBD-5005
- Other IDs
- U1111-1207-6263
- Acronym
- INTENT
- Status last verified
- Sep 2023
- First submitted
- 1 May 2018
- Last updated
- 29 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- International, Multicentre, Non-Interventional Study To Evaluate Disease Control And Treatment Pattern In Patients With Moderate To Severe Inflammatory Bowel Disease In Real Life Practice
- ClinicalTrials.gov ID
- NCT03532932
- Acronym / sponsor ID
- INTENT / IBD-5005
- Keywords
- Drug therapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,990 participants (actual)
- Lead sponsor
- TakedaIndustry (pharma, biotech, devices)
- Study start
- 20 Jul 2018 (actual)
- Primary completion
- 8 Nov 2021 (actual)
- Study completion
- 8 Nov 2021 (actual)
- First posted
- 22 May 2018 (actual)
- Results
- Posted 29 Mar 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD).
Detailed description
This is a non-interventional, retrospective and prospective study of participants with IBD. This study will collect data to provide accurate and comprehensive information related to treatment patterns associated with biologics use or non-biological therapy in participants with moderate to severe UC and CD in routine clinical practice.
The study will have retrospective data collection from past records of participants within the last 2 years before participant's enrollment. The prospective part of the study will include one year of observation and data collection after the participant's enrollment in the study.
The study will enroll approximately 2000 participants. Participants will be enrolled in one of the two groups:
- UC Participants
- CD Participants
This multi-center trial will be conducted in Russia, Belarus and Kazakhstan. The overall period of observation in this study will be approximately 12 months. Participants will make 2 visits within their routine practice to the clinic after the enrollment into the study including a final visit at Month 12.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| UC Participants | – | –Participants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies. |
| CD Participants | – | –Participants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants diagnosed with moderate to severe UC or CD will be observed both retrospectively and prospectively.
Key inclusion criteria (3 listed)
- Has confirmed diagnosis of CD or UC for at least 2 years prior to enrollment in the study.
- Has a moderate to severe IBD flare at the time of enrollment or in participant anamnesis within 2 years before enrollment treated with steroids or/ and immunosuppressive agents or/ and biologic therapy. IBD flare(s) must be confirmed in the source documentation.
- Current treatment with steroids or/ and immunosuppressive agents or/ and 5-aminosalicylate (ASA) or/ and biologic therapy.
Key exclusion criteria (5 listed)
- Current or previous (within the last two years) indeterminate or not classified colitis.
- Changing of IBD type in anamnesis (that is, from UC to CD, etc) within the last two years.
- Current, previous (within the last two years) or planned (for the next one year) participation in interventional clinical trial.
- Presenting of mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- Has received previous treatment with biologic therapy/immunosuppressive agents for conditions other than IBD ever in their lifetime.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Treatment pattern with biologics agents or non-biological therapy included unique treatments combinations, Like>5-ASA1(Start with 5-ASA:5-ASA→Systemic biologics [SB] +/- STER+/-standard therapy[ST]),>5ASA2(without [w/o] STER),>5ASA3(5-ASA→STER+/-ST),>5ASA4(5-ASA→IS),>5ASA 5(5-ASA→5-ASA+/-IS),>5ASA6(5-ASA→ NOTR),>5ASA7(5-ASA),>NOTR1(NOTR→Biologics [BIO]+/-ST+/-STER),>NOTR 2(TR→ST+/-STER),>NOTR 3(NOTR),>IS1(IS→SB+STER+/-ST),>IS2(IS→SB+ST w/o STER),>IS 3(IS→STER+/-ST),>IS4(IS→5-ASA),>IS5(IS→NOTR),>IS6(IS→5-ASA+IS),>IS7(IS mono),>IS+5ASA1(IS+5-ASA→SB +/-ST),>IS+5ASA2(IS+5-ASA→SB ±ST w/o STER),>IS+5ASA3(IS+5-ASA→STER+/-ST),>IS+5ASA4(IS+5-ASA→NOTR),>IS+5ASA5(IS+5-ASA→IS),>IS+5ASA6(IS+5-ASA→5-ASA),>IS+5ASA7(IS+5-ASA),>BIO1(SB+/-STER+/-ST→withdrawal [w/d] of SB+ST+/-STER),>BIO2(SB+/-STER+/-ST),>BIO3(SB+/-STER+/-ST→NOTR),>BIO4(SB+/-STER+/-ST→SB mono),>STER1(STER+/-ST→w/d of STER+SB+/-ST),>STER2(STER+/-ST→w/d of STER+ST),>STER3(STER+/-ST→SB+STER+/-ST),>STER4(STER+/-ST→NOTR),>STER5(STER+/-ST).
12 secondary outcomes
Number of Participants Stratified by Location of Disease
Time frame: Within 1 year prior to Baseline (Visit 1)
Number of Participants Stratified by Disease Severity
Time frame: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
Number of Participants Based on Usage of Methods for Documentation of Disease Activity in Routine Practice
Time frame: From Baseline Visit (Day 1) up to 12 months
Number of Assessments Using Different Methods in Participants With UC and CD Disease Activity
Time frame: From Baseline Visit (Day 1) up to 12 months
UC Participants: Percentage of Participants Who Achieved Combined Clinical and Endoscopic Remission Based on Mayo Index
Time frame: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
CD Participants: Percentage of Participants Who Achieved Clinical Remission Based on HBI
Time frame: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period
Number of Participants With at Least One Episode of Failure of Biological or Non-biological Therapy
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Number of Participants Who Needed Treatment Adjustments Based on Disease Activity Assessment
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Stratified by Achieving the Treatment Goals
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Challenges of Implementing a T2T Strategy in UC and CD Participants in Real Clinical Practice
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Hospitalizations Due to Complications, IBD Related Surgeries, and Disability Determination in Participants With Moderate to Severe UC and CD
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Percentage of Participants Based on Surgical Treatment by Indications and Type of Surgeries
Time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Related trials for Colitis, Ulcerative
RecruitingPhase 2
A Study of AC-101 Tablets in Patients With Ulcerative Colitis
Ulcerative Colitis (UC)
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
Not yet recruitingPhase 1
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
RecruitingPhase 4
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis, Crohn's Disease
Recruiting
Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel Disease
Crohn Disease and Ulcerative Colitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Study Director study director
Takeda
36 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colitis, Ulcerative and Crohn Disease, run by Takeda at 36 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in Russia, Kazakhstan, Belarus. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD (time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024.